Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
IRLAB Therapeutics AB (publ)
IRLAB-AIRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson's; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden. Address: Arvid Wallgrens Backe 20, Gothenburg, Sweden, 413 46
Analytics
Objectif de Cours de WallStreet
440.47 SEKRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés IRLAB-A
Analyse des dividendes IRLAB-A
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes IRLAB-A
Valorisation des titres IRLAB-A
financières IRLAB-A
Résultats | 2019 | Dynamique |